title: Capsaicin pre-treatment provides neurovascular protection against neonatal hypoxic-ischemic brain injury in rats.
abstract: Capsaicin, a transient receptor potential vanilloid 1 (TRPV1) agonist, has recently been shown to provide neuroprotection against brain injury in experimental adult models of cerebral ischemia. Accordingly, in this study, we investigated the way in which capsaicin-mediated TRPV1 modulation could attenuate damage in an experimental hypoxic-ischemic (HI) neonatal brain injury model. The Rice-Vannucci method was used in 10-day-old rat pups by performing unilateral carotid artery ligation followed by 2 h of hypoxia (8% O2 at 37°C). Capsaicin was administered intraperitoneally (0.2 mg/kg or 2.0 mg/kg) at 3 h pre-HI or 1 h post-HI. Post assessment included measurement of infarction volume at 24 and 72 h in addition to an assessment of the vascular dynamics of the middle cerebral artery (MCA) at 6 h post-HI. The results indicated that pre-treatment with capsaicin reduced infarction volume significantly with either low-dose or high-dose treatment. Pre-treatment also improved myogenic tone and decreased apoptotic changes in the distal MCA. We concluded that capsaicin pre-treatment may provide neurovascular protection against neonatal HI.
authors: Department of Anesthesiology, Loma Linda Medical Center, Loma Linda, CA 92354, USA.
authors: Nikan H
authors: NH
authors: Khatibi
authors: Vikram
authors: V
authors: Jadhav
authors: Shelton
authors: S
authors: Charles
authors: Jeffrey
authors: J
authors: Chiu
authors: John
authors: J
authors: Buchholz
authors: Jiping
authors: J
authors: Tang
authors: John H
authors: JH
authors: Zhang
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D000831:Animals, Newborn; D020520:Brain Infarction / Q000209:etiology / Q000517:prevention & control; D002211:Capsaicin / Q000008:administration & dosage*; D004195:Disease Models, Animal; D004334:Drug Administration Schedule; D005786:Gene Expression Regulation / Q000187:drug effects; D020244:Infarction, Middle Cerebral Artery / Q000473:pathology / Q000517:prevention & control*; D020768:Middle Cerebral Artery / Q000187:drug effects* / Q000473:pathology; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D010751:Phosphopyruvate Hydratase / Q000378:metabolism; D051381:Rats; D050916:TRPV Cation Channels / Q000378:metabolism; D013778:Tetrazolium Salts; D013997:Time Factors; D014841:von Willebrand Factor / Q000378:metabolism
chemical_list: D018696:Neuroprotective Agents; D050916:TRPV Cation Channels; D013778:Tetrazolium Salts; C493922:Trpv1 protein, rat; D014841:von Willebrand Factor; C009591:triphenyltetrazolium; D010751:Phosphopyruvate Hydratase; D002211:Capsaicin